We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Teva's Leukemia Drug sNDA Granted Priority Review by the FDA
Read MoreHide Full Article
Teva Pharmaceutical Industries Ltd. (TEVA - Free Report) announced that the FDA has accepted the supplemental New Drug Application (sNDA) for Trisenox on a priority review basis.
The company is looking to expand the label of Trisenox to include its use in combination with all-trans retinoic acid for the treatment of newly diagnosed patients with low-to-intermediate risk of acute promyelocytic leukemia (APL)
The eligible APL patients should have t(15;17) translocation or PML/RAR-alpha gene expression.
With the FDA granting priority review, a decision is expected in the first quarter of 2018.
We remind investors that Trisenox is currently approved for induction of remission and consolidation in refractory/relapsed APL patients with t(15;17) translocation or PML/RAR-alpha gene expression. The patients should have received prior treatment with retinoid and anthracycline chemotherapy.
The drug is approved in the EU as both first-line and second-line treatment for this indication.
Shares of the company were up almost 4.5% on Tuesday, riding on the momentum following the appointment of H. Lundbeck’s chief Kare Schultz as its new CEO and sale of Paragard devices to Cooper Companies, Inc. (COO - Free Report) for $1.1 billion. However, shares of Teva have underperformed the industry so far this year due to challenges in the U.S. generic industry. The company’s shares have plunged 46.7% while the industry has lost 14.5% in that period.
According to the company, Trisenox, in combination with retinoic acid, can increase survival rates, dramatically reduce the risk of relapse, and help avoid chemotherapy-related side effects in low-to-intermediate risk APL patients. It has been seen in clinical studies that Trisenox, in combination with retinoic acid, can lead to a 99% overall survival rate with almost no relapse after more than four years (50 months) of median follow-up.
Teva Pharmaceutical Industries Limited Price and Consensus
Aduro’s loss estimates have narrowed 9.6% to $1.32 for 2017 and 20% to $1.24 for 2018 over the last 60 days. The company delivered an average earnings beat of 2.53% for the four trailing quarters.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Image: Bigstock
Teva's Leukemia Drug sNDA Granted Priority Review by the FDA
Teva Pharmaceutical Industries Ltd. (TEVA - Free Report) announced that the FDA has accepted the supplemental New Drug Application (sNDA) for Trisenox on a priority review basis.
The company is looking to expand the label of Trisenox to include its use in combination with all-trans retinoic acid for the treatment of newly diagnosed patients with low-to-intermediate risk of acute promyelocytic leukemia (APL)
The eligible APL patients should have t(15;17) translocation or PML/RAR-alpha gene expression.
With the FDA granting priority review, a decision is expected in the first quarter of 2018.
We remind investors that Trisenox is currently approved for induction of remission and consolidation in refractory/relapsed APL patients with t(15;17) translocation or PML/RAR-alpha gene expression. The patients should have received prior treatment with retinoid and anthracycline chemotherapy.
The drug is approved in the EU as both first-line and second-line treatment for this indication.
Shares of the company were up almost 4.5% on Tuesday, riding on the momentum following the appointment of H. Lundbeck’s chief Kare Schultz as its new CEO and sale of Paragard devices to Cooper Companies, Inc. (COO - Free Report) for $1.1 billion. However, shares of Teva have underperformed the industry so far this year due to challenges in the U.S. generic industry. The company’s shares have plunged 46.7% while the industry has lost 14.5% in that period.
According to the company, Trisenox, in combination with retinoic acid, can increase survival rates, dramatically reduce the risk of relapse, and help avoid chemotherapy-related side effects in low-to-intermediate risk APL patients. It has been seen in clinical studies that Trisenox, in combination with retinoic acid, can lead to a 99% overall survival rate with almost no relapse after more than four years (50 months) of median follow-up.
Teva Pharmaceutical Industries Limited Price and Consensus
Teva Pharmaceutical Industries Limited Price and Consensus | Teva Pharmaceutical Industries Limited Quote
Zacks Rank & Stocks to Consider
Teva currently has a Zacks Rank #5 (Strong Sell). Aduro Biotech, Inc. is a better-ranked stock in the healthcare sector, carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Aduro’s loss estimates have narrowed 9.6% to $1.32 for 2017 and 20% to $1.24 for 2018 over the last 60 days. The company delivered an average earnings beat of 2.53% for the four trailing quarters.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>